Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.

A closely anticipated trial has concluded with disappointing results for Novo Nordisk's blockbuster drug semaglutide, the ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

A new study hints that pregnant people who have previously taken drugs like Ozempic may face a higher risk of certain poor ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...